Research and Markets has announced the addition of the "Rhino-Conjunctivitis Global Clinical Trials Review, H2, 2016" report to their offering.
The clinical trial report provides an overview of Rhino-Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Rhino-Conjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.
Scope of the Report:
- The report provides a snapshot of the global clinical trials landscape;
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status;
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company;
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment;
- The Report provides enrollment trends for the past five years;
-
Report provides latest news for the past three months.
Reasons to buy:
- Assists in formulating key business strategies with regards to investment;
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost;
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities;
- Supports understanding of trials count and enrollment trends by country in global therapeutics market;
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted trials;
-
Facilitates clinical trial assessment of the indication on a global,
regional and country level.
Companies Mentioned:
- ALK-Abello A/S
- Circassia Pharmaceuticals Plc
- Laboratorios LETI SL
- Merck KGaA
- Stallergenes Greer plc
- Merck & Co Inc
- Droege International Group AG
-
Inflamax Research Inc
For more information about this report visit http://www.researchandmarkets.com/research/l72ndc/rhinoconjunctivit
View source version on businesswire.com: http://www.businesswire.com/news/home/20170123006029/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Clinical
Trials, Optical